Home     About SABCS     Press Releases     Media     Event Photos     Past Symposia     Satellite Symposia     Patient Advocates     FAQs     Contact Us



Registration       Hotel       Presenter Instructions       Support & Exhibits     2014 Overview       Program       Faculty     Travel & Transportation      

Schedule at a Glance
 
Daily Schedule:
Tue. 12/9/2014
Wed. 12/10/2014
Thu. 12/11/2014
Fri. 12/12/2014
Sat. 12/13/2014
 
Poster Sessions:
Poster Session 1
Poster Session 2
Poster Session 3
Poster Session 4
Poster Session 5
Poster Session 6
 
Poster Session OT1
Poster Session OT2
Poster Session OT3
 
Poster Discussions:
Poster Discussion 1
Poster Discussion 2
Poster Discussion 3
Poster Discussion 4
Poster Discussion 5
Poster Discussion 6
 

Program Schedule   >  Daily Schedule - Wednesday, December 10, 2014

 
Tuesday | Wednesday | Thursday | Friday | Saturday
WEDNESDAY, DECEMBER 10, 2014
7:00 am - 5:15 pm Registration - Bridge Hall  
     
7:00 am - 8:00 am Continental Breakfast - Hall C  
     
8:00 am - 8:15 am WELCOME AND OPENING REMARKS – Hall D  
     
8:15 am - 8:45 am PLENARY LECTURE 1 – Hall D  
     
 

Genome-Directed Therapeutics for Endocrine Therapy Resistant ER+ Breast Cancer

 
 

Matthew J. Ellis, MD, PhD

Baylor College of Medicine

Houston, TX

 
     
8:45 am - 11:15 am

GENERAL SESSION 1 – Hall D

Moderator: Rachel Schiff, PhD, Baylor College of Medicine, Houston, TX

 
     
8:45 am S1-01.  TransCONFIRM: The correlative analysis of breast tumors from patients with advanced hormone receptor positive disease identifies a genetic signature associated with decreased benefit from single agent fulvestrant  
 

Jeselsohn RM, Barry WT, Zhao J, Buchwalter G, Guarducci C, Migliaccio I, Biagioni C, Bonechi M, Laing N, Rukazenkov Y, Winer EP, Brown M, Di Leo A, Malorni L. Dana Farber Cancer Institute, Boston, MA; Translational Research Unit, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy; "Sandro Pitigliani" Medical Oncology Unit, IstitutoToscano Tumori, Prato, Italy; AstraZeneca Pharmaceuticals, Macclesfield, United Kingdom.

 
     
9:00 am

S1-02. Prognostic effects of gene mutation in estrogen receptor positive breast cancer

 
  Griffith OL, Griffith M, Luo J, Hundall J, Miller CA, Larson DE, Fulton R, Wilson RK, Liu S, Leung S, Nielsen TO, Mardis ER, Ellis MJ. Washington University School of Medicine, St Louis, MO; University of British Columbia, Vancouver, BC, Canada.
     
9:15 am S1-03. Identification of base pair mutations and structural rearrangements acquired in breast cancer metastases including a novel hyperactive ESR1-DAB2 fusion gene specifically in hormone-resistant recurrence  
 

Hartmaier RJ, Puhalla SL, Oesterreich S, Bahreini A, Davidson NE, Brufsky AM, Lee AV.  Women's Cancer Research Center, University of Pittsburgh Cancer Institute & Magee Women's Research Center, Pittsburgh, PA; Department of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, PA; Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA.

 
     
9:30 am

S1-04.  Exome sequencing of post-menopausal ER+ breast cancer (BC) treated pre-surgically with aromatase inhibitors (AIs) in the POETIC trial (CRUK/07/015)

 
 

Gellert P, Segal CV, Gao Q, Li T, Miller CA, Mardis E, Martin L-A, Holcombe C, Skene A, Bliss J, Robertson J, Smith I, Dowsett M, POETIC Trial Management Group and Trialists. Institute of Cancer Research, London, United Kingdom; The Genome Institute at Washington University, St Louis, MO; Royal Liverpool University Hospital, Liverpool, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Marsden Hospital, London, United Kingdom; University of Nottingham, Nottingham, United Kingdom; POETIC Trial Management Group and Trialists.

 
     
9:45 am S1-05.  In-depth genomic analysis of ER+ breast cancers during development of endocrine resistance
 
 

Dixon JM, Turnbull AK, Fan C, Parker JS, He X, Arthur L, Martinez-Perez C, Renshaw L, Perou C. University of Edinburgh, Edinburgh, United Kingdom; Comprehensive Cancer Centre, Chapel Hill, NC.

 
     
10:00 am S1-06. Stromal tumor-infiltrating lymphocytes(S-TILs): In the alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefit  
 

Perez EA, Ballman KV, Anderson SK, Thompson EA, Badve SS, Bailey H, Baehner FL. Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Indiana

University, Indianapolis, IN; Genomic Health Inc., Redwood City, CA; University of California, San Francisco, San Francisco, CA.

 
     
10:15 am

S1-07. HER2 T cell dependent bispecific antibody (HER2-TDB) for treatment of HER2 positive breast cancer

 
 

Junttila TT, Li J, Johnston J, Hristopoulos M, Clark R, Ellerman D, Wang B-E, Li Y, Mathieu M, Li G, Young J, Luis E, Lewis Phillips G, Stefanich E, Spiess C, Polson A, Irving B, Scheer JM, Junttila MR, Dennis MS, Kelley R, Totpal K, Ebens A.  Genentech, South San Francisco, CA.

 
     
10:30 am

S1-08. Reduced tumor lymphocytic infiltration in the residual disease (RD) of post-neoadjuvant chemotherapy (NAC) triple-negative breast cancers (TNBC) is associated with Ras/MAPK activation and poorer survival

 
 

Balko JM, Denkert C, Salgado R, O'Hely M, Savas P, Beavis PA, Darcy PK, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sanders ME, Cook RS, Wang K, Miller VA, Stephens PJ, Yelensky R, Pinto JA, Doimi F, Gomez H, Arteaga CL, Loi S.  Peter MacCallum Cancer Center, Sydney, Australia; Charité University, Berlin, Germany; Institute Jules Bordet, Brussels, Belgium; WEHI University, Melbourne, Australia; Yale University, New Haven, CT; Vanderbilt University, Nashville, TN; Foundation Medicine, Cambridge, MA; Oncosalud, Lima, Peru; Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Peru.

 
     
10:45 am S1-09. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer  
  Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Dolled-Filhart M, Emancipator K, Gonzalez EJ, Houp J, Pathiraja K, Karantza V, Iannone R, Gause CK, Cheng JD, Buisseret L. University of Chicago Department of Medicine, Chicago, IL; University of Washington Department of Medicine, Seattle, WA; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Sheba Medical Center, Tel Hashomer, Israel; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel; Yale School of Medicine, New Haven, CT; Merck & Co., Inc., Whitehouse Station, NJ; Institut Jules Bordet, Université Libre de Bruxelles, Bruxelles, Belgium.  
     
11:00 am S1-10. Discussant  
 

Mary L. (Nora) Disis, MD
University of Washington

Seattle, WA

 
     
11:15 am - 12:00 pm William L. McGuire Memorial Lecture - Hall D  
 

Pharmacogenomics in the Quest for Precision Endocrine Therapy of Breast Cancer

James N. Ingle, MD

Mayo Clinic

Rochester, MN
 
     
12:00 pm - 1:00 pm LUNCH AND EXHIBITS  
     
1:00 pm - 2:00 pm CLINICAL SCIENCE FORUM - Hall D  
 

Contralateral Prophylactic Mastectomy: Controversies and Trends

Moderator: Ismail Jatoi, MD, PhD, FACS, UT Health Science Center, San Antonio, TX

 
 

 

Clinical implications of contralateral prophylactic mastectomy

Ismail Jatoi, MD, PhD, FACS

UT Health Science Center

San Antonio, TX

Contralateral prophylactic mastectomy: Patient preferences and risk perceptions

Ann Partridge, MD, MPH

Dana-Farber Cancer Institute

Boston, MA

 

What are the implications for reconstruction following contralateral prophylactic mastectomy?

Andrea L. Pusic, MD, MHS

Memorial Sloan-Kettering Cancer Center

New York, NY
 
     
1:00 pm - 2:00 pm BASIC SCIENCE FORUM - Ballroom B  
 

Discovering Rational Combination Therapies

Moderator: Carlos Arteaga, MD, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN

 
 

 

Targeting DNA repair in triple negative breast cancer therapy

Alan D'Andrea, MD

Dana-Farber Cancer Institute

Boston, MA

 

Finding effective combination therapies through functional genetics

René Bernards, PhD

Netherlands Cancer Institute

Amsterdam, NETHERLANDS
 
     
1:00 pm - 2:00 pm SPECIAL FORUM - Ballroom A  
 

Role of Advocates in Community, Research and Policy

Moderator: Susan W. Rafte, Pink Ribbons Project, Houston, TX

 
 

 

Community Advocacy

Valarie Worthy, RN, BSN

Duke University

Durham, NC

 

Research Advocacy

Elizabeth S. Frank, BA, Ed.M

Dana-Farber Cancer Institute

Boston, MA

 

Policy Advocacy

Jane Perlmutter, PhD, MBA

Gemini Group

Ann Arbor, MI

 

Funmi Olopade, MD, Panelist

University of Chicago

Chicago, IL

 

Eric P. Winer, MD, Panelist

Dana-Farber Cancer Institute

Boston, MA

 
     
2:15 pm - 3:15 pm

SUSAN G. KOMEN® BRINKER AWARDS FOR SCIENTIFIC DISTINCTION LECTURES – Hall D

 

The Basic Science Award is presented to a researcher whose scientific

discoveries or novel technologies have added substantively to our

understanding of the basic biology of breast cancer and the intrinsic

molecular processes that drive the disease, and/or whose work has

bridged the gap between basic research and patient care. This year the

award is being presented to:

 

Joan S. Brugge, PhD

Harvard Medical School

Boston, MA

Building Upon Advances in Cancer Research to Improve Therapeutic Strategies in the Future

 

The Clinical Research Award is presented to a clinical or translational

researcher who has advanced the identification of new prevention,

detection or treatment approaches for breast cancer and promoted

their incorporation into clinical care. This year the award is being

presented to:

 

Mitchell Dowsett, PhD, FMedSci

Royal Marsden Hospital and Institute of Cancer Research

London, UNITED KINGDOM

What relevance have hormones for breast cancer in the genomic era

 
     
3:15 pm - 5:00 pm

GENERAL SESSION 2 – Hall D

Moderator: Aleix Prat, MD, PhD, Hospital Clinic de Barcelona, Barcelona, SPAIN

 
     
3:15 pm S2-01.  Theranostic multiparametric tests improve residual risk assessment in early luminal breast cancer  
 

Bartlett JMS, Sabine VS, Haider S, Drake C, Crozier C, Yao CQ, Brookes CL, van de Velde CJH, Hasenburg A, Kieback DG, Markopoulos C, Dirix LY, Seynaeve C, Rea DW, Boutros PC.  Ontario Institute for Cancer Research, Toronto, ON, Canada; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom; Leiden University Medical Center, Leiden, Netherlands; University Hospital, Freiburg, Germany; Klinikum Vest Medical Center, Marl, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, Netherlands; University of Toronto, Toronto, ON, Canada.

 
     
3:30 pm S2-02. The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results  
 

Krop I, Johnston S, Mayer IA, Dickler M, Ganju V, Forero-Torres A, Melichar B, Morales S, de Boer R, Gendreau S, Derynck M, Lackner M, Spoerke J, Yeh R-F, Levy G, Ng V, O'Brien C, Savage H, Xiao Y, Wilson T, Lee SC, Petrakova K, Vallentin S, Yardley D, Ellis M, Piccart M, Perez EA, Winer E, Schmid P. 
Dana-Farber Cancer Institute, Boston, Boston, MA; Royal Marsden Hospital, London, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN; Department of Medicine Memorial Sloan Kettering Cancer Center, NY, NY; Peninsula Oncology Centre, Melbourne, Australia; University of Alabama, Birmingham, Birmingham, AL; Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic; Hospital Arnau de Vilanova, Lleida, Spain; Royal Melbourne Hospital, Parkville, Australia; Genentech, South San Francisco, CA; National University Hospital, Singapore, Singapore, Singapore; Masaryk Memorial Cancer Institute, Brno, Czech Republic; Herlev University Hospital, Herlev, Denmark; Sarah Cannon Research Institute, Nashville, TN; Washington University School of Medicine, St. Louis, MO; Institut Jules Bordet, Universit
é Libre de Bruxelle, Brussels, Belgium; Mayo Clinic, Jacksonville, FL; Barts Cancer Institute, Queen Mary University London, London, United Kingdom.

 
     
3:45 pm S2-03. Preoperative window of opportunity study of the PI3K inhibitor pictilisib (GDC-0941) plus anastrozole vs anastrozole alone in patients with ER+, HER2-negative operable breast cancer (OPPORTUNE study)
 
 

Schmid P, Pinder SE, Wheatley D, Macaskill J, Zammit C, Hu J, Price R, Bundred N, Hadad S, Shia A, Lim L, Sarker S-J, Gazinska P, Woodman N, Korbie D, Trau M, Mainwaring P, Parker P, Purushotham A, Thompson AM.  Barts Cancer Institute, Charterhouse Square, London, United Kingdom; Guys and St Thomas Hospital, London, United Kingdom; Royal Cornwall Hospital, Cornwall, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; St. Barts Hospital, London, United Kingdom; King's College Hospital, London, United Kingdom; University Hospital South Manchester, Manchester, United Kingdom; Royal Hallamshire Hospital, Sheffield, United Kingdom; Australian Institute for Bioengineering and Nano-technology, St Lucia, Australia; ICON Cancer Care, Brisbane, Australia; Kings College London, London, United Kingdom; MD Anderson Cancer Centre, Texas, TX.

 
     
4:00 pm S2-04. Comprehensive molecular characterization of invasive lobular breast tumors  
 

Ciriello G, Gatza ML, Hoadley KA, Zhang H, Rhie SK, Bowlby R, Wilkerson MD, Kandoth C, McLellan M, Cherniack A, Laird PW, Sander C, King TA, Perou CM. Memorial Sloan Kettering Cancer Center, New York, NY; University of North Carolina, Chapel Hill, NC; Broad Institute of MIT and Harvard, Cambridge, MA; University of Southern California; British Columbia Cancer Agency; Washington University in St. Louis.

 
     
4:15 pm S2-05. Characterization and clinical relevance of the genomic alterations defining lobular breast cancer  
  Desmedt C, Gundem G, Zoppoli G, Pruneri G, Biganzoli E, Fornili M, Fumagalli D, Rothé F, Brown D, Van Loo P, Brohée S, Vincent D, Keddoumi N, Majjaj S, Rouas G, Van Brussel T, Lambrechts D, Metzger O, Galant C, Bertucci F, Piccart M, Larsimont D, Viale G, Campbell PJ, Sotiriou C.  Institut Jules Bordet- Université Libre de Bruxelles, Belgium; Wellcome Trust Sanger Institute- The Cancer Genome Project, United Kingdom; European Institute of Oncology, Italy; University of Milan- Fondazione IRCCS Istituto Nazionale Tumori, Italy; Vesalius Research Center, VIB, Campus Gasthuisberg, Leuven, Belgium; Dana-Farber Cancer Institute; Université Catholique de Louvain, Belgium; Institut Paoli Calmettes, France.  
     
4:30 pm S2-06. Survival advantage of anastrozol compared to tamoxifen for lobular breast cancer in the ABCSG-8 study  
  Knauer M, Gruber C, Dietze O, Greil R, Stöger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Singer C, Dubsky P, Jakesz R, Fitzal F, Steger G, Bartsch R, Filipits M, Fesl C, Gnant M.  Breast Center St. Gallen, Switzerland; Hospital of the Sisters of Charity, Linz, Austria; Paracelsus Medical University, Salzburg, Austria; Medical University, Graz, Austria; Medical University, Vienna, Austria; Landesklinikum, Wiener Neustadt, Austria; ABCSG.  
     
4:45 pm S2-07. TBA  
     
5:00 pm - 7:00 pm

POSTER DISCUSSION 1: Tumor Immunity – Ballroom A

 
     
 

Kim Lyerly, MD - Co-Discussant

Duke University

Durham, NC

and

Carsten Denkert, MD - Co-Discussant

Institut für Pathologie

Berlin, GERMANY

 
     
5:00 pm - 7:00 pm

POSTER DISCUSSION 2: Randomized Trials: Successes and Failures – Ballroom B

 
     
 

Joseph A. Sparano, MD - Co-Discussant

Montefiore Medical Center

Bronx, NY

and

William Barry, PhD - Co-Discussant

Dana-Farber Cancer Institute

Boston, MA

 
     
5:00 pm - 7:00 pm POSTER SESSION 1 & reception – Halls A-B
 
     
 

Imaging and Screening

Breast Imaging - MRI
Breast Imaging - Other Methods

 

P1-01

P1-02

     
 

Tumor Cell and Molecular Biology

Genetics - Germline Changes

Genetics - Somatic Changes

Gene Therapy

Epigenetics

Tumor Progression, Invasion, and Metastasis

Metabolism and Breast Cancer

 

P1-03

P1-04

P1-05

P1-06

P1-07

P1-08

     
 

Psychosocial, Quality of Life, and Educational Aspects

Survivorship Research

Cost-Effectiveness

Disparities and Barriers to Care

 

P1-09

P1-10

P1-11

     
 

Treatment

Adjuvant Endocrine Therapy

Advanced Endocrine Therapy

Neoadjuvant Endocrine Therapy

Radiotherapy

Breast Conservation

Rescheduled Posters

 

P1-12

P1-13

P1-14

P1-15

P1-16

P1-17

     
 

Ongoing Clinical Trials 1

Targeted Therapies

Circulating Tumor Cells

Local Therapies

Radiation Therapy

 

OT1-1

OT1-2

OT1-3

OT1-4

     
7:30 pm - 9:30 pm

OPEN SATELLITE EVENT presented by Research to Practice - Marriott Rivercenter, Grand Ballroom (3rd Floor)

What Oncology Clinicians Want to Know - Addressing Current Questions and Controversies in the Management of Breast Cancer


 
 

Website: http://www.researchtopractice.com/Meetings/SA2014

 
     
 
Tuesday | Thursday | Friday | Saturday
 
 
Home | About SABCS | Press Releases | Media | Event Photos | Past Symposia | Satellite Symposia | Patient Advocates | FAQs | Contact Us
Registration | Hotel | Presenter Instructions | Support & Exhibits | 2014 Overview | Program | Faculty | Travel & Transportation

Rich Markow, Director, Symposia
Cancer Therapy & Research Center at UT Health Science Center San Antonio

7979 Wurzbach Road, MC 8224 San Antonio, TX 78229 USA
Phone: 210-450-1550    Fax: 210-450-1560    Email: sabcs@uthscsa.edu
       line
Copyright 2014 SABCS. All rights reserved. - Privacy Policy